GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (SHSE:603259) » Definitions » ROE % Adjusted to Book Value

Wuxi AppTec Co (SHSE:603259) ROE % Adjusted to Book Value : 2.93% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Wuxi AppTec Co ROE % Adjusted to Book Value?

Wuxi AppTec Co's ROE % for the quarter that ended in Dec. 2023 was 11.47%. Wuxi AppTec Co's PB Ratio for the quarter that ended in Dec. 2023 was 3.92. Wuxi AppTec Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 2.93%.


Wuxi AppTec Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Wuxi AppTec Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co ROE % Adjusted to Book Value Chart

Wuxi AppTec Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.21 1.17 1.58 4.02 4.82

Wuxi AppTec Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.44 3.79 6.83 4.40 2.93

Competitive Comparison of Wuxi AppTec Co's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Wuxi AppTec Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuxi AppTec Co's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Wuxi AppTec Co's ROE % Adjusted to Book Value falls into.



Wuxi AppTec Co ROE % Adjusted to Book Value Calculation

Wuxi AppTec Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=18.89% / 3.92
=4.82%

Wuxi AppTec Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=11.47% / 3.92
=2.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuxi AppTec Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuxi AppTec Co (SHSE:603259) Business Description

Traded in Other Exchanges
Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.

Wuxi AppTec Co (SHSE:603259) Headlines

No Headlines